Article

Bisphosphonate Therapy for Metastatic Bone Disease: The Pivotal Role of Nurses in Patient Education

Margaret Fitch

Cathy Maxwell

bisphosphonate, nurse role
ONF 2008, 35(4), 709-713. DOI: 10.1188/08.ONF.709-713

Purpose/Objectives: To describe the role of bisphosphonate therapy for metastatic bone disease and skeletal-related events associated with some of the most common malignancies, and to highlight the importance and untapped potential of nurses intervening in the education and treatment of patients with these issues.

Data Sources: Contemporary evidence-based studies on the prevalence and impact on quality of life in metastatic bone disease and skeletal-related events, and all major clinical trials describing the efficacy of bisphosphonates for the treatment of metastatic bone disease.

Data Synthesis: Metastatic bone disease is a common consequence of cancer that impairs patient quality of life. Bisphosphonate therapy is effective in preventing or delaying complications associated with metastatic bone disease.

Conclusions: Bisphosphonate therapy can help preserve functional independence and improve the quality of life for many patients with cancer. Poor adherence to bisphosphonate therapy frequently is caused by patients not understanding how the drug works or why they need it. Premature discontinuation of bisphosphonate therapy leaves patients at risk for painful and debilitating skeletal-related events, which reduces their functional independence and impairs their activities of daily living.

Implications for Nursing: Nurses are uniquely positioned to educate patients and their caregivers about the need to begin or continue taking bisphosphonates for treatment of metastatic bone disease and associated skeletal-related events. Nurses often are the most appropriate healthcare providers for counseling patients with metastatic cancer about personal and family issues and for communicating the needs and concerns of patients to their physicians.

Jump to a section

    References

    Berenson, J. R. (2005). Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist, 10(1), 52-62.
    Berenson, J. R., lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., et al. (1998). Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. Journal of Clinical Oncology, 16(2), 593-602.
    Coleman, E. A., Coon, S., Hall-Barrow, J., Richards, K., Gaylor, D., & Stewart, B. (2003). Feasibility of exercise during treatment for multiple myeloma. Cancer Nursing, 26(5), 410-419.
    Coleman, R. E. (1997). Skeletal complications of malignancy. Cancer, 80(8, Suppl.), 1588-1594.
    Cooper, C. (1997). The crippling consequences of fractures and their impact on quality of life. American Journal of Medicine, 103(2a), 13S-19S.
    Cramer, J. A., Amonkar, M. M., Hebborn, A., & Altman, R. (2005). Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Current Medical Research and Opinion, 21(9), 1453-1460.
    Delea, T. E., McKiernan, J. M., Brandman, J., Sung, J., Raut, M., & Oster, G. (2005). Effects of skeletal complications on total medical care costs in patients with bone metastases of solid tumors [Abstract 8094]. Presentation at the 41st American Society of Clinical Oncology Annual Meeting, Orlando, FL.
    Saad, F., Olsson, C., & Schulman, C. C. (2004). Skeletal morbidity in men with prostate cancer: Quality-of-life considerations throughout the continuum of care. European Urology, 46(6), 731-739.
    Sabino, M., & Mantyh, P. (2005). Pathophysiology of bone cancer pain. Journal of Supportive Oncology, 3(1), 15-24.
    Sambrook, P., Olver, I., & Goss, A. (2006). Bisphosphonates and osteonecrosis of the jaw. Australian Family Physician, 35(10), 801-803.
    Singh, B., Berry, J. A., Shoher, A., Ayers, G. D., Wei, C., & Lucci, A. (2007). COX-2 involvement in breast cancer metastasis to bone. Oncogene, 26(26), 3789-3796.
    Siris, E. S., Harris, S. T., Rosen, C. J., Barr, C. E., Arvesen, J. N., Abbott, T. A., et al. (2006). Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 U. S. claims databases. Mayo Clinic Proceedings, 81(8), 1013-1022.
    Sriussadaporn, S., Phoojaroenchanachai, M., Ploybutr, S., Plengvidhya, N., Peerapatdit, T., Nitiyanant, W., et al. (2007). Hypercalcemia of malignancy: A study of clinical features and relationships among circulating levels of calcium, parathyroid hormone, and parathyroid hormone-related peptide. Journal of the Medical Association of Thailand, 90(4), 663-671.
    Vogel, C. L., Yanagihara, R. H., Wood, A. J., Schnell, F. M., Henderson, C., Kaplan, B. H., et al. (2004). Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. Oncologist, 9(6), 687-695.
    Weinfurt, K. P., Anstrom, K. J., Castel, L. D., Schulman, K. A., & Saad, F. (2006). Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer. Annals of Oncology, 17(6), 986-989.
    Weinfurt, K. P., Li, Y., Castel, L. D., Saad, F., Timbie, J. W., Glendenning, G. A., et al. (2005). The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Annals of Oncology, 16(4), 579-584.
    Weitzman, R., Sauter, N., Eriksen, E. F., Tarassoff, P. G., Lacerna, L. V., Dias, R., et al. (2007). Critical review: Updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients. Critical Reviews in Oncology/Hematology, 62(2), 148-152.
    Wu, S., Dahut, W. L., & Gulley, J. L. (2007). The use of bisphosphonates in cancer patients. Acta Oncologica, 46(5), 581-591.
    DeVita, V. T., Jr., Hellman, S., & Rosenberg, S. A. (2001). Cancer: Principles and practice of oncology (6th ed.). Philadelphia: Lippincott Williams and Wilkins.
    Gobel, B. H. (2005). Metabolic emergencies. In J. K. Itano & K. N. Taoka (Eds.), Core curriculum for oncology nursing (4th ed., pp. 383-421). Philadelphia: Elsevier Saunders.
    Halfdanarson, T. R., Hogan, W. J., & Moynihan, T. J. (2006). Oncologic emergencies: Diagnosis and treatment. Mayo Clinic Proceedings, 81(6), 835-848.
    Heatley, S., Lothman, H., & Major, P. (2006). Gastrointestinal side effects can reduce compliance with oral bisphosphonate therapy in cancer patients. Presentation at the Fifth European Oncology Nursing Society Spring Convention, Innsbruck, Austria.
    Heidenreich, A., Hofmann, R., & Engelmann, U. H. (2001). The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. Journal of Urology, 165(1), 136-140.
    Hillner, B. E., Ingle, J. N., Berenson, J. R., Janjan, N. A., Albain, K. S., Lipton, A., et al. (2000). American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. Journal of Clinical Oncology, 18(6), 1378-1391.
    Hoer, A., Gol, D., Gothe, H., Schiffhorst, G., Brandman, J., & Haussler, B. (2005). Rates and determinants of patient persistency with oral bisphosphonates in cancer patients. Supportive Care in Cancer, 13, 428.
    Horiuchi, T., Miyachi, T., Arai, T., Nakamura, T., Mori, M., & Ito, H. (1997). Raised plasma concentrations of parathyroid hormone related peptide in hypercalcemic multiple myeloma. Hormone and Metabolic Research, 29(9), 469-471.
    Lee, J. K., Chuang, M. J., Lu, C. C., Hao, L. J., Yang, C. Y., Han, T. M., et al. (1997). Parathyroid hormone and parathyroid hormone related protein assays in the investigation of hypercalcemic patients in hospital in a Chinese population. Journal of Endocrinological Investigation, 20(7), 404-409.
    Lipton, A., Theriault, R. L., Hortobagyi, G. N., Simeone, J., Knight, R. D., Mellars, K., et al. (2000). Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials. Cancer, 88(5), 1082-1090.
    Major, P. (2004). Gastrointestinal adverse events can reduce compliance with oral bisphosphonate therapy and result in early study termination [Abstract 58]. Presentation at the "What Is New in Bisphosphonates?" 7th Workshop on Bisphosphonates—From the Laboratory to the Patient, Davos, Switzerland.
    Major, P., Lortholary, A., Hon, J., Abdi, E., Mills, G., Menssen, H. D., et al. (2001). Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials. Journal of Clinical Oncology, 19(2), 558-567.
    McKiernan, J., Delea, T. E., Liss, M., Edelsberg, J. S., Brandman, J., Sung, J. C., et al. (2004). Impact of skeletal complications on total medical care costs in prostate cancer patients with bone metastases [Abstract 6057]. Presentation at the 40th American Society of Clinical Oncology Annual Meeting, New Orleans, LA.
    Mock, V., Pickett, M., Ropka, M. E., Muscari, L. E., Stewart, K. J., Rhodes, V. A., et al. (2001). Fatigue and quality of life outcomes of exercise during cancer treatment. Cancer Practice, 9(3), 119-127.
    Mundy, G. R., & Yoneda, T. (1995). Facilitation and suppression of bone metastasis. Clinical Orthopaedics and Related Research, 312, 34-44.
    National Cancer Institute. (2008). Pain (PDQ®). Retrieved May 7, 2008, from http://www.nci.nih.gov/cancertopics/pdq/supportivecare/pain/HealthProfessional
    Novartis Pharmaceuticals Corporation. (2006a). Summit meeting to discuss the role of nurses in administering bisphosphonate treatments for bone metastases. Brussels, Belgium: European Oncology Nursing Society.
    Novartis Pharmaceuticals Corporation. (2006b). Zometa® [Package insert]. East Hanover, NJ: Author.
    Pavlakis, N., Schmidt, R. L., & Stockler, M. (2005). Bisphosphonates for breast cancer. Cochrane Database of Systematic Reviews, 3, CD003474.
    Petrut, B., Trinkaus, M., Simmons, C., & Clemons, M. (2008). A primer of bone metastases management in breast cancer patients. Current Oncology, 15(Suppl. 1), S50-S57.
    Pickett, M., Mock, V., Ropka, M. E., Cameron, L., Coleman, M., & Podewils, L. (2002). Adherence to moderate-intensity exercise during breast cancer therapy. Cancer Practice, 10(6), 284-292.
    Reid, I. R., Brown, J. P., Burckhardt, P., Horowitz, Z., Richardson, P., Trechsel, U., et al. (2002). Intravenous zoledronic acid in postmenopausal women with low bone mineral density. New England Journal of Medicine, 346(9), 653-661.
    Rosen, L. S., Gordon, D. H., Dugan, W., Jr., Major, P., Eisenberg, P. D., Provencher, L., et al. (2004). Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer, 100(1), 36-43.
    Rosen, L. S., Gordon, D. H, Tchekmedyian, N. S., Yanagihara, R., Hirsh, V., Krzakowski, M., et al. (2004). Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, phase III, doubleblind, placebo-controlled trial. Cancer, 100(12), 2613-2621.
    Saad, F. (2003). Bisphosphonates in prostate cancer: Where are we and where should we go. Journal of the National Cancer Instute, 95(17), 1262-1263.
    Saad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., et al. (2002). A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Journal of the National Cancer Institute, 94(19), 1458-1468.
    Lipton, A. (1997). Biophosphates and breast carcinoma. Cancer, 80(8, Suppl.), 1668-1673.
    Lipton, A. (2005). Management of bone metastases in breast cancer. Current Treatment Options in Oncology, 6(2), 161-171.